Spiegel David R, Kolb Richard
Department of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
Clin Neuropharmacol. 2011 Jan-Feb;34(1):36-8. doi: 10.1097/WNF.0b013e318209cef2.
Irritable bowel syndrome (IBS) is a functional gastrointestinal tract disorder characterized by recurrent abdominal pain or discomfort, where the onset is associated with either a change in form of stool or its frequency and is often improved with defecation. Alosetron, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, was an effective drug in treating women with diarrhea-predominant IBS. However, the drug was removed from the United States market because of its association with ischemic colitis and serious complications related to severe constipation. Presented here is a case report of a 66-year-old woman with a history of panic disorder and major depression and a 1-year history of IBS-mixed type, which she reported to be "worsened by panic attacks." On the basis that mirtazapine is a potent 5-HT3 receptor antagonist and has demonstrated pain relief from somatic symptoms, we treated our patient with mirtazapine, which seems to have decreased her diarrhea and constipation symptoms, and her psychopathological symptoms.
肠易激综合征(IBS)是一种功能性胃肠道疾病,其特征为反复出现腹痛或不适,症状发作与大便形态或排便频率的改变相关,且常于排便后缓解。阿洛司琼是一种5-羟色胺-3(5-HT3)受体拮抗剂,曾是治疗腹泻型肠易激综合征女性患者的有效药物。然而,由于该药与缺血性结肠炎及严重便秘相关的严重并发症有关,已从美国市场撤市。本文报告了一例66岁女性患者,有惊恐障碍和重度抑郁症病史,肠易激综合征混合型病史1年,患者自述“惊恐发作会加重病情”。基于米氮平是一种强效5-HT3受体拮抗剂且已证明可缓解躯体症状性疼痛,我们用米氮平对该患者进行治疗,结果似乎减轻了她的腹泻和便秘症状以及精神病理症状。